Alfred D Kingsley
CIK 1229339 · Chairman · last filed 2023-07-03
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
BTX.WS price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
NEW YORK, NY 10022
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| LCTX | Chairman | 5,845,596 | $1.00 | $5.85M | $0 | 5 | 2023-07-03 |
| Insight Molecular Diagnostics Inc. (OCX) Delisted | Director | 25,394 | $3.20 | $81.3K | $7.9K | 15 | 2023-06-27 |
| Lineage Cell Therapeutics, Inc. (BTX.WS) Delisted | See Remarks | 5,846,906 | — | — | -$3.27M | 33 | 2018-07-03 |
| Asterias Biotherapeutics, Inc. (AST.WS) Delisted | Director | 9,000 | — | — | $11.7K | 1 | 2016-06-10 |
| Asterias Biotherapeutics, Inc. (AST) Delisted | Director | 5,000 | — | — | $21.6K | 3 | 2016-03-01 |
Recent Filings · Page 3 of 6
59 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-07-03 | Lineage Cell Therapeutics, Inc. (BTX.WS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-08-21 | Lineage Cell Therapeutics, Inc. (BTX.WS) Delisted | Disp (D) | −300,000 | -$843.0K | EDGAR |
| 2017-08-02 | Lineage Cell Therapeutics, Inc. (BTX.WS) Delisted | Sell (S) | −150,000 | -$420.0K | EDGAR |
| 2017-07-05 | Lineage Cell Therapeutics, Inc. (BTX.WS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-06-19 | Insight Molecular Diagnostics Inc. (OCX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-01-06 | Lineage Cell Therapeutics, Inc. (BTX.WS) Delisted | Other (J) | −238,469 | $0 | EDGAR |
| 2016-07-05 | Lineage Cell Therapeutics, Inc. (BTX.WS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-06-10 | Asterias Biotherapeutics, Inc. (AST.WS) Delisted | Buy (P) | +4,000 | $11.7K | EDGAR |
| 2016-03-01 | Asterias Biotherapeutics, Inc. (AST) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-02-18 | Insight Molecular Diagnostics Inc. (OCX) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.